Shigeo Muro Japan

2022~2025 Vice Director, Nara Medical University Hospital 2018 Professor, Department of Respiratory Medicine, Nara Medical university 2017 Associate Professor, Graduate School of Medicine, Kyoto University 2001 Kyoto university Hospital 1998 Research Fellow, Meakins Christie Laboratories, McGill university, Montreal, Quebec,Canada 1994 Graduate School of Medicine, Kyoto University 1989 Kitano Medical Research Institute, Public Interest Incorporated Foundation, Tazuke kofukai 1989 Resident in Internal Medicine, Chest Disease Research Institute Hospital, Kyoto University
Job Title
Professor
Faculty / Department / Division
Respiratory Medicine
Institution / Organisation
Nara Medical University

19 November 2026, Thursday

20 November 2026, Friday

Time Session
08:00
08:30
APSR’s Leadership in Advancing Respiratory Medicine and Sciences in Asia
Yoshinori Hasegawa Speaker Japan
Ahmad Izuanuddin Ismail Chairperson Malaysia
Established in 1986 to advance respiratory medicine and combat respiratory diseases in the Asia-Pacific, the Asian Pacific Society of Respirology (APSR) has grown into a major international society and a Founding Member of the Forum of International Respiratory Societies (FIRS). The APSR’s mission is to advance and disseminate knowledge of the respiratory system in health and disease across the Asia-Pacific and globally, aiming to bridge regional healthcare disparities and elevate research, education, and clinical practice. Guided by its vision to reshape the future of respiratory medicine through innovative, patient-centered, equitable, and sustainable care, the Society promotes collaboration among researchers and clinicians to provide optimal respiratory care tailored to the region’s diverse healthcare infrastructures and disease burdens. This lecture reviews the past year's achievements and key initiatives across five core pillars: hosting the annual APSR Congress, publishing official journals (Respirology and Respirology Case Reports), nurturing early-career researchers through education and fellowships, leading Assembly and Section activities, and advancing global advocacy and international partnerships. A defining feature of the APSR is its "en bloc" society membership system. By integrating national respiratory societies, this strategy driven rapid expansion, rendering the APSR the largest respiratory society in the region. This sheer scale grants the Society strong leverage in international negotiations and policy advocacy alongside global bodies such as the WHO, ATS, and ERS. The en bloc membership system has expanded the APSR's reach and strengthened collaboration among respiratory societies across the Asia-Pacific. Building on this foundation, the APSR aims to encourage greater individual member participation and raise awareness of benefits such as journal access, educational programs, and fellowships. Closer partnerships with national and regional societies, together with clearer communication of the APSR's achievements, will further strengthen members' sense of connection and shared purpose. These efforts will enhance membership value and support the Society's sustainable growth.
Ballroom 3, Lower Ground Floor
13:00
14:00
14:00
15:00
Ernest Mau Ern Poh Chairperson Malaysia
Lalitha Pereirasamy Chairperson Malaysia
  • Michelle Gong Speaker United States
    Respiratory medicine's evidence base is skewed by Asia's near-absence from clinical trials, and that this is not merely an equity problem but a scientific one — Asia holds close to 60% of the world's population and therefore the largest absolute number of pneumonia deaths, yet the diversity within the continent is treated as a single category. The diversity extends to management and inflammatory profiles in ARDS. This has implications with personalized care and trials. Precision therapy already shows access disparities in Asia mirroring those documented for molecular testing in lung cancer elsewhere. Chronic disease phenotypes diverge as well — COPD risk centers more on biomass fuel and prior TB exposure than smoking; lung cancer shows higher rates of non-smoking adenocarcinoma and EGFR mutation; bronchiectasis trends toward post-TB incidence and a dry phenotype with lower bacterial burden; asthma sub-phenotypes vary country to country. But this diversity in Asia are also opportunities for research. This can be done by leveraging existing data sources and collecting new registry data (retrospective or prospective) to establish disease burden. One can start locally and then link data across sites. Collaborate for team science, and participate in pragmatic comparative-effectiveness and implementation trials that embed into routine care without placebo or drug preparation are also opportunities. Given limited resources, researchers should choose questions no one has answered locally and collect only the key data that can be done routinely during clinical practice. Professional meetings are an important route to multi-country teams and research. One key element is the need to invest in training physicians in research methods so that they can lead research in their own country. ATS MECOR (Methods in Epidemiologic, Clinical and Operations Research) is one model for building that capacity.
  • Shigeo Muro Speaker Japan
    Respiratory medicine increasingly relies on evidence generated across different populations. Yet clinical findings from one region may not fully describe patients in another. Asia is highly diverse, and differences may exist both between Asian and Western patient groups and among populations within Asia. As an example of diversity within Asia, the frequency of EGFR mutations in lung adenocarcinoma varies across Asian populations. Turning to COPD, selected observational studies from Asia, Europe and the United States suggest differences in body mass index, chronic bronchitis and exacerbation history across the groups studied. These findings should not be taken as uniform characteristics of all Asian patients. Breathlessness, reduced daily activity and long-term outcomes also deserve attention, even when exacerbations are less frequent. Another major challenge is underdiagnosis. Studies from Japan, Korea and China have identified gaps in COPD diagnosis or previous spirometry use. Efforts to address these gaps must take local healthcare systems and resources into account. Japan's Health Japan 21 programme includes a national target to reduce COPD mortality. To support this goal, the Japanese Respiratory Society is pursuing COMORE-By2032, an ongoing initiative that links public awareness and earlier medical visits with spirometry, smoking cessation and continued care. Global evidence is essential, but improving COPD care also requires locally appropriate action and collaboration across the Asia-Pacific region.
  • Marc Miravitlles Speaker Spain
  • Q&A
Ballroom 4, Lower Ground Floor
16:30
18:00

22 November 2026, Sunday